<DOC>
	<DOC>NCT01032122</DOC>
	<brief_summary>The purpose of this study is to determine whether rituximab as an adjuvant therapy in clinical stage IIIc / IV (no evidence of disease, AJCC (American Joint Committee on Cancer) 2002) melanoma patients is safe and prolongs overall survival and disease-free interval.</brief_summary>
	<brief_title>Rituximab in Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically verified nonocular melanoma stage IIIc/IV, no evidence of disease ECOG (Eastern Cooperative Oncology Group) performance status &gt; 2 Ocular melanoma Immunodeficiency syndromes or hypogammaglobulinaemia Active autoimmune diseases Treatment with immunosuppressive agents other than steroids Depressed bone marrow function (Leukopenia &lt;3000, platelet count &lt;100.000) Cardiac insufficiency NYHA (New York Heart Association) IV active Hepatitis B,C, or HIV infection Pregnancy or lactation Interstitial pulmonary disease Former treatment with antiCD20 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>melanoma</keyword>
	<keyword>rituximab</keyword>
	<keyword>metastatic</keyword>
	<keyword>stage IIIc/IV</keyword>
	<keyword>stem cell</keyword>
	<keyword>overall survival</keyword>
	<keyword>disease free interval</keyword>
	<keyword>anti-CD20 therapy</keyword>
</DOC>